Role of urinary cathelicidin LL-37 and human ��-defensin 1 in uncomplicated Escherichia coli urinary tract infections.

Karen L Nielsen, Pia Dynesen, Preben Larsen, Lotte Jakobsen, Paal S Andersen, Niels Frimodt-M��ller
Author Information
  1. Karen L Nielsen: Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen S, Denmark.

Abstract

Cathelicidin (LL-37) and human ��-defensin 1 (hBD-1) are important components of the innate defense in the urinary tract. The aim of this study was to characterize whether these peptides are important for developing uncomplicated Escherichia coli urinary tract infections (UTIs). This was investigated by comparing urinary peptide levels of UTI patients during and after infection to those of controls, as well as characterizing the fecal flora of participants with respect to susceptibility to LL-37 and in vivo virulence. Forty-seven UTI patients and 50 controls who had never had a UTI were included. Participants were otherwise healthy, premenopausal, adult women. LL-37 MIC levels were compared for fecal E. coli clones from patients and controls and were also compared based on phylotypes (A, B1, B2, and D). In vivo virulence was investigated in the murine UTI model by use of selected fecal isolates from patients and controls. On average, UTI patients had significantly more LL-37 in urine during infection than postinfection, and patient LL-37 levels postinfection were significantly lower than those of controls. hBD-1 showed similar urine levels for UTI patients and controls. Fecal E. coli isolates from controls had higher LL-37 susceptibility than fecal and UTI E. coli isolates from UTI patients. In vivo studies showed a high level of virulence of fecal E. coli isolates from both patients and controls and showed no difference in virulence correlated with the LL-37 MIC level. The results indicate that the concentration of LL-37 in the urinary tract and low susceptibility to LL-37 may increase the likelihood of UTI in a complex interplay between host and pathogen attributes.

References

  1. Nephron. 2000 May;85(1):34-40 [PMID: 10773753]
  2. Trends Immunol. 2007 Aug;28(8):340-5 [PMID: 17627888]
  3. PLoS One. 2010 Dec 14;5(12):e15580 [PMID: 21179490]
  4. Appl Environ Microbiol. 2001 Apr;67(4):1619-27 [PMID: 11282614]
  5. J Allergy Clin Immunol. 2011 May;127(5):1302-4.e1 [PMID: 21310475]
  6. Lancet. 1987 Apr 11;1(8537):824-6 [PMID: 2882232]
  7. Antimicrob Agents Chemother. 2000 Jan;44(1):156-63 [PMID: 10602738]
  8. Mol Cell Probes. 1998 Jun;12(3):171-3 [PMID: 9664579]
  9. PLoS Pathog. 2010 Jul 22;6(7):e1001010 [PMID: 20661475]
  10. Immunotechnology. 1995 May;1(1):65-72 [PMID: 9373334]
  11. J Allergy Clin Immunol. 2005 Feb;115(2):252-8 [PMID: 15696078]
  12. Antimicrob Agents Chemother. 1998 Sep;42(9):2206-14 [PMID: 9736536]
  13. Genes Immun. 2007 Jul;8(5):439-43 [PMID: 17508030]
  14. Ann Epidemiol. 2000 Nov;10(8):509-15 [PMID: 11118930]
  15. Mol Microbiol. 2009 Jun;72(5):1137-46 [PMID: 19400793]
  16. Kidney Int. 2013 Apr;83(4):615-25 [PMID: 23302724]
  17. Nature. 2011 Jan 20;469(7330):419-23 [PMID: 21248850]
  18. Lancet Infect Dis. 2004 Oct;4(10):631-5 [PMID: 15451491]
  19. Water Sci Technol. 2004;50(1):193-8 [PMID: 15318508]
  20. Res Microbiol. 2008 May;159(4):288-93 [PMID: 18434099]
  21. AIDS. 2006 Aug 1;20(12):1673-5 [PMID: 16868452]
  22. J Clin Invest. 1998 Apr 15;101(8):1633-42 [PMID: 9541493]
  23. PLoS One. 2012;7(2):e31712 [PMID: 22359618]
  24. Environ Microbiol. 2008 Oct;10(10):2484-96 [PMID: 18518895]
  25. Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1121-9 [PMID: 22033854]
  26. J Am Soc Nephrol. 2006 Dec;17(12):3267-3272 [PMID: 37001006]
  27. Scand J Gastroenterol. 2008 Mar;43(3):299-307 [PMID: 18938660]
  28. Genes Immun. 2008 Jan;9(1):57-60 [PMID: 17960157]
  29. Appl Environ Microbiol. 2000 Oct;66(10):4555-8 [PMID: 11010916]
  30. J Biol Chem. 1998 Feb 6;273(6):3718-24 [PMID: 9452503]
  31. AIDS. 2004 Jul 23;18(11):1598-600 [PMID: 15238780]
  32. Infect Immun. 2002 Jun;70(6):3053-60 [PMID: 12010997]
  33. Eur J Clin Invest. 2008 Oct;38 Suppl 2:21-8 [PMID: 18826478]

MeSH Term

Adult
Animals
Antimicrobial Cationic Peptides
Case-Control Studies
Disease Models, Animal
Escherichia coli
Escherichia coli Infections
Feces
Female
Host-Pathogen Interactions
Humans
Mice
Microbial Sensitivity Tests
Urinary Tract Infections
Virulence
beta-Defensins
Cathelicidins

Chemicals

Antimicrobial Cationic Peptides
DEFB1 protein, human
beta-Defensins
Cathelicidins

Word Cloud

Created with Highcharts 10.0.0LL-37UTIpatientscontrolsurinarycolifecaltractlevelsvirulenceEisolatessusceptibilityvivoshowedhuman��-defensin1hBD-1importantuncomplicatedEscherichiainfectionsinvestigatedinfectionMICcomparedsignificantlyurinepostinfectionlevelCathelicidincomponentsinnatedefenseaimstudycharacterizewhetherpeptidesdevelopingUTIscomparingpeptidewellcharacterizingfloraparticipantsrespectForty-seven50neverincludedParticipantsotherwisehealthypremenopausaladultwomenclonesalsobasedphylotypesB1B2DmurinemodeluseselectedaveragepatientlowersimilarFecalhigherstudieshighdifferencecorrelatedresultsindicateconcentrationlowmayincreaselikelihoodcomplexinterplayhostpathogenattributesRolecathelicidin

Similar Articles

Cited By